This letter formally transmits the summary of an oral briefing we gave on December 8, 2008, and subsequent agency comments. We gave this briefing in response to Senate Report 110-129, accompanying the 2008 Financial Services and General Government Appropriations Bill. In accordance with direction in that report, and in consultation with House and Senate Appropriation Committee staff, we are reporting on the Office of National Drug Control Policy's (ONDCP) Counterdrug Technology Assessment Center (CTAC). Specifically, we address issues pertaining to CTAC's use of funds since fiscal year 2003, the ONDCP Director's approach to funding decisions for research and development, CTAC's measures of performance, and CTAC's reorganization in 2007.
Recommendations for Executive Action
|Office of National Drug Control Policy||1. The ONDCP Director should identify the role that different factors play in funding decisions, and document the basis used to select particular research and development project concepts for funding, including the rationale for selecting certain project concepts over others.|